|
Fig. 1 Osimertinib-resistant NSCLC cell lines were established, and the IC50 values of osimertinib and anlotinib were determined. An MTT assay was used to explore cell viability in (A) H1975 and H1975-OR cells and (B) PC9 and PC9-OR cells treated with different concentrations of osimertinib. A CCK-8 assay was conducted to explore the proliferative capacities of (C) H1975 and H1975-OR cells and (D) PC9 and PC9-OR cells. An MTT assay was conducted to measure cell viability in (E) H1975 and H1975-OR cells and (F) PC9 and PC9-OR cells treated with different concentrations of anlotinib. P values were calculated using two-way ANOVA analysis; ***, P<0.001. OD, optical density; NSCLC, non-small cell lung cancer; IC50, half-maximal inhibitory concentration; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide; CCK-8, Cell Counting Kit-8; ANOVA, analysis of variance.